A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

[1] Sekulic A(2012)Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 2171-2179

[2] Migden MR(2010)Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction–liquid chromatographic–tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 785-790

[3] Oro AE(2012)Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects Br J Clin Pharmacol 74 788-796

[4] Dirix L(2011)Phase 1 trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors Clin Cancer Res 17 2502-2511

[5] Lewis KD(2011)Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449) J Med Chem 54 2592-2601

[6] Hainsworth JD(2011)Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding Clin Cancer Res 17 2512-2520

[7] Solomon JA(2011)A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry Drug Metab Dispos 39 1460-1467

[8] Yoo S(2011)Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 879 2119-2126

[9] Arron ST(2013)Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers J Cardiovasc Pharmacol 61 83-89

[10] Friedlander PA(2012)Reducing adverse effects of proton pump inhibitors Am Fam Physician 86 66-70

[1] Sekulic A(2012)Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 2171-2179

[2] Migden MR(2010)Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction–liquid chromatographic–tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 785-790

[3] Oro AE(2012)Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects Br J Clin Pharmacol 74 788-796

[4] Dirix L(2011)Phase 1 trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors Clin Cancer Res 17 2502-2511

[5] Lewis KD(2011)Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449) J Med Chem 54 2592-2601

[6] Hainsworth JD(2011)Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding Clin Cancer Res 17 2512-2520

[7] Solomon JA(2011)A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry Drug Metab Dispos 39 1460-1467

[8] Yoo S(2011)Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 879 2119-2126

[9] Arron ST(2013)Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers J Cardiovasc Pharmacol 61 83-89

[10] Friedlander PA(2012)Reducing adverse effects of proton pump inhibitors Am Fam Physician 86 66-70